iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 clinical trials
Also written FT538.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FT538
- 4
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Masonic Cancer Center, University of Minnesota (3) · Fate Therapeutics (1)
Studies
Open first, then newest update. How each study uses iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedPhase 1Masonic Cancer Center, University of MinnesotaNCT05708924Written as FT538
- FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT04714372Written as FT538
- Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV ViremiaWithdrawnPhase 1Masonic Cancer Center, University of MinnesotaNCT05700630Written as FT538
- FT538 in Subjects With Advanced Hematologic MalignanciesTerminatedPhase 1Fate TherapeuticsNCT04614636Written as FT538